Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome

Core Viewpoint - Quoin Pharmaceuticals is launching a video series titled "Living with Netherton" to raise awareness about Netherton Syndrome, a rare genetic disease, coinciding with Rare Disease Day on February 28, 2025 [1][2][8] Company Initiatives - The "Living with Netherton" series is part of the broader NETHERTON NOW campaign aimed at increasing understanding and advocacy for Netherton Syndrome [2][5] - Future episodes will continue to highlight patient and family experiences, emphasizing the need for awareness and treatment options [4] Patient Experience - The first episode features Carmon McTigue, whose son faced a long and challenging journey to diagnosis, ultimately revealing the lack of approved treatments for Netherton Syndrome [3][5] - The story illustrates the severe impacts of the disease, including multiple hospitalizations and complications such as MRSA [3][6] Disease Overview - Netherton Syndrome is caused by mutations in the SPINK5 gene, leading to severe symptoms including excessive skin shedding and a high risk of complications [6][10] - Up to 20% of infants born with Netherton Syndrome do not survive, highlighting the urgent need for increased awareness and research [6] Product Development - Quoin's lead candidate, QRX003, is currently in four clinical trials, with recent data suggesting its potential efficacy as a treatment for Netherton Syndrome [7][10] - QRX003 is designed to improve skin barrier function and normalize skin shedding in patients [10] Community Engagement - The NETHERTON NOW website serves as a resource hub for patients and families, offering educational materials and updates on research advancements [9][12]